Denali slips as Takeda exits dementia drug partnership

Denali Therapeutics

06/04/2026 16:57

** Shares of Denali Therapeutics DNLI.O fall 4.3% to $19.76, snapping a three-day winning streak

** Japan's Takeda Pharmaceutical 4502.T will end their partnership to develop DNL593, an experimental drug for a rare and aggressive form of dementia, DNLI said on Friday

** Decision was driven by strategic considerations and is not related to efficacy or safety data, Denali said

** The partnership was signed in 2018, to develop and commercialize three therapies for neurodegenerative diseases

** Denali expects to report results from the ongoing early-to-mid stage trial of DNL593 by the end of 2026

** Including session moves, stock up 19.3% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))